IRVINE, CA. -- Edwards Lifesciences Corporation, the global leader in the science of heart valves and hemodynamic monitoring, today announced it has received CE Mark in Europe for valve-in-valve ...

An analyst earlier this month took aim at what’s behind a big run-up in shares of Irvine medical device maker Edwards Lifesciences Corp.: a new type of heart valve that doesn’t require major surgery.

Edwards Lifesciences Corp. unveiled a new option in its heart valve franchise on Tuesday. The Irvine-based valve maker’s Ascendra procedure uses an aortic heart valve replacement system that is less ...

TORONTO, ON -- Edwards Lifesciences Corporation, the global leader in the science of heart valves and hemodynamic monitoring, today announced that three-year clinical outcomes of its EDWARDS INTUITY ...

NEW ORLEANS, April 3 (Reuters) - A heart valve replacement technique developed by Edwards LifeSciences Corp <EW.N> that spares patients open-heart surgery had a slightly lower death rate at one year, ...

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s SAPIEN M3 mitral valve replacement system received CE Mark for the transcatheter treatment of ...

The heart valve specialist reported a second straight quarter of double-digit TAVR sales growth and credited recent study results with driving a “sense of urgency” for treating patients.

CHICAGO (Reuters) - Edwards LifeSciences Corp's less-invasive replacement heart valve alleviates symptoms such as fatigue and breathlessness better than standard medical therapy, data released on ...

Edwards Lifesciences has secured European approval for its transcatheter tricuspid valve replacement system, which the company described as the first minimally invasive therapy of its kind to receive ...

IRVINE, Calif., July 15, 2020 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, ...

Edwards Lifesciences (NYSE:EW) develops medical devices for structural heart disease, transcatheter procedures, and critical care, highlighting operational performance in the NYSE Composite sector.

(Reuters) - Shares of Edwards Lifesciences Corp jumped 13 percent on Monday after a U.S. court temporarily halted sales of competitor Medtronic Inc's heart valve implant that uses a less-invasive ...